Wirksamkeit des Eisen(III)-hydroxidPolymaltose-Komplexes bei Eisenmangel

S. Serra; H.-J. Groß; H. Cario

doi:10.1055/s-0038-1629350

Kinder- und Jugendmedizin, Table of Contents

Kinder- und Jugendmedizin 2013; 13(05): 362-366
DOI: 10.1055/s-0038-1629350

Originalarbeit

Schattauer GmbH

Wirksamkeit des Eisen(III)-hydroxidPolymaltose-Komplexes bei Eisenmangel

Ein Praxisbericht zur Behandlung der Eisenmangel -anämie bei Kindern und JugendlichenEfficacy of iron(III) hydroxide polymaltose complex for iron deficiencyA real-life experience of treatment of iron deficiency anaemia in children and adolescents

S. Serra

¹Medizinische Fakultät, Universität Würzburg

,

H.-J. Groß

²Zentrale Einrichtung Klinische Chemie, Universitätsklinikum Ulm

,

H. Cario

³Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Ulm

› Author Affiliations

Abstract

Zusammenfassung

Die Option der Behandlung von Kindern mit einer Eisenmangelanämie mit dem Eisen(III)-hydroxid-Polymaltose-Komplex (EPK) wird in aktuellen Übersichtsartikeln und Leitlinien kaum berücksichtigt. Ziel: Basierend auf Behandlungsdaten aus einer hämatologischen Ambulanz soll die Wirksamkeit des EPK bei der Therapie der Eisenmangelanämie mit aktuellen Ergebnissen unterstrichen werden. Patienten, Methode: Es erfolgte eine retrospektive Analyse von 57 Patienten (Alter: 5–185 Monaten) mit der Diagnose Eisenmangelanämie, die mit EPK behandelt wurden. Ergebnisse: Die EPK-Therapie führte zu signifikanten Veränderungen von Hämoglobin, Hämatokrit, MCV, Serumferritin und löslichem Transferrinrezeptor (sTFR) sowie des sTFR-Index. Bis auf zwei Fälle von Obstipation traten keine unerwünschten Arzneimittelwirkungen auf. Schlussfolgerung: Die Therapie der Eisenmangelanämie mit EPK ist im Alltag der pädiatrischen Praxis erfolgreich und gut verträglich. Sie bietet eine effektive therapeutische Alternative zu Eisen(II)- Salzen.

Summary

For various reasons, the majority of current reviews and guidelines on the treatment of iron deficiency in children does not or only preliminary mention the option to treat with iron(III) hydroxide polymaltose complex (IPC). Aim: We aimed to demonstrate the efficacy of IPC treatment based on daily practice treatment data from a haematological out-patient clinic. Patients, methods: We performed a retrospective analysis including 57 patients (age: 5–185 months) diagnosed with iron deficiency anaemia who were treated with IPC. Results: Treatment led to significant changes of haemoglobin, haematocrit, MCV, serum ferritin, soluble transferrin receptor (sTFR), and sTFR-Index. Apart from two cases with constipation no side effects of treatment had been observed. Conclusion: Despite the limitations of such an analysis it can be concluded that treatment of iron deficiency anaemia with IPC in the paediatric real-life setting is effective and safe, and represents an effective alternative to the treatment with iron(II) salts.

Schlüsselwörter

Eisenmangel - Anämie - Eisen(III)-hydroxid Polymaltose-Komplex

Keywords

Iron deficiency - anaemia - iron(III) hydroxide polymaltose complex

Full Text

References

Literatur
1 WHO. Global health risks. Mortality and burden of disease attributable to selected major risks. 2009 [cited 04.11.2012]. www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf
2 Looker AC, Dallman PR, Carroll MD. et al. Prevalence of iron deficiency in the United States. JAMA 1997; 277: 973-976.
3 Male C, Persson LA, Freeman V. et al. Prevalence of iron deficiency in 12-mo-old infants from 11 European areas and influence of dietary factors on iron status (Euro-Growth study). Acta Paediatr 2001; 90: 492-498.
4 Saha L, Pandhi P, Gopalan S. et al. Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women. MedGenMed 2007; 9: 1
5 Jacobs P, Wormald L. The bioavailability of an iron polymaltose complex for treatment of iron deficiency. J Med 1979; 10 (04) 279-85.
6 Jacobs P, Wormald LA, Gregory MC. Absorption of iron polymaltose and ferrous sulphate in rats and humans. A comparative study. S Afr Med J 1979; 55: 1065-1072.
7 Toblli JE, Brignoli R. Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis. Arzneimittelforschung 2007; 57 (06) A431-438.
8 Geisser P, Burckardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33.
9 Afzal M, Qureshi SM, Lutafullah M. et al. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children. J Pak Med Assoc 2009; 59: 764-768.
10 Borbolla JR, Cicero RE, Dibildox MM. et al. Complejo polimaltosado férrico vs sulfato ferroso en el tratamiento de la anemia por deficiencia de hierro en lactantes. Rev Mex Pediatr 2000; 67: 63-67.
11 Murahovschi J, Stein ML, Caraffa RC. et al. Tratamento da ferropenia e da anemia ferropênica com o complexo de hidróxido de ferro polimaltosado por via oral, de crianças em fase de recuperação de infecções respiratórias. Ensaio duplo-cego, comparativo com sulfato ferroso. Rev Paul Pediatr 1987; 5: 97-104.
12 Schmidt BJ, Morais MB, Fisberg M. et al. Comparaç o terapêutica entre o sulfato ferroso e o ferro trivalente em forma de complexo de hidróxido férrico polimaltosado na deficiencia orgánica de ferro. A Folha Med 1985; 90: 25-29.
13 Amaral D, Galimberti G, Cuesta S. et al. Comparative evaluation of efficacy and tolerance of iron polymaltose complex and ferrous sulphate for treatment of iron deficiency anemia in infants. Rev Fac Cien Med Univ Nac Cordoba 2012; 69: 97-101.
14 Behnisch W, Muckenthaler M, Kulozik A. Eisenmangelanämie - Leitlinie der Gesellschaft für Pädiatrische Onkologie und Hämatologie (2010). 2010 [cited 04.11.2012]; Available from: www.awmf.org/uploads/tx_szleitlinien/025-021l_S1_Eisenmangelanaemie.pdf
15 Goddard AF, James MW, McIntyre AS, Scott BB, British Society of G. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309-1316.
16 Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol 2011; 4: 177-184.
17 Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011; 64: 287-296.
18 Toblli JE, Cao G, Olivieri L, Angerosa M. Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology 2008; 82: 127-137.
19 Jacobs P, Wood L, Bird AR. Erythrocytes: Better Tolerance of Iron Polymaltose Complex Compared with Ferrous Sulphate in the Treatment of Anaemia. Hematology 2000; 5: 77-83.
20 Yasa B, Agaoglu L, Unuvar E. Efficacy, tolerability, and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: A randomized trial in pediatric patients with iron deficiency Anemia. Int J Pediatr 2011; 524520
21 Langstaff RJ, Geisser P, Heil WG, Bowdler JM. Treatment of iron deficiency anaemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate. Br J Clin Res 1993; 4: 191-198.
22 Arnon S, Shiff Y, Litmanovitz I. et al. The efficacy and safety of early supplementation of iron polymaltose complex in preterm infants. Am J Perinatol 2007; 24: 95-100.
23 Haliotis FA, Papanastasiou DA. Comparative study of tolerability and efficacy of iron protein succinylate versus iron hydroxide polymaltose complex in the treatment of iron deficiency in children. Int J Clin Pharmacol Ther 1998; 36: 320-325.
24 Sas G, Nemesanszky E, Brauer H, Scheffer K. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittelforschung 1984; 34: 1575-1579.
25 Bopche AV, Dwivedi R, Mishra R, Patel GS. Ferrous sulfate versus iron polymaltose complex for treatment of iron deficiency anemia in children. Indian Pediatr 2009; 46: 883-885.
26 Rote Liste Frankfurt (Main): Rote Liste Service; 2012